Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech

Fineline Cube Apr 16, 2025

Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...

Company Drug Policy / Regulatory

US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security

Fineline Cube Apr 16, 2025

The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...

Company

Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech

Fineline Cube Apr 16, 2025

US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...

Company Drug

BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study

Fineline Cube Apr 15, 2025

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...

Company Drug

Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males

Fineline Cube Apr 15, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has initiated a Phase III...

Company Drug

Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease

Fineline Cube Apr 15, 2025

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors

Fineline Cube Apr 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...

Company Drug

Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case

Fineline Cube Apr 15, 2025

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...

Company Drug

Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe

Fineline Cube Apr 15, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study

Fineline Cube Apr 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval...

Company Drug

CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors

Fineline Cube Apr 15, 2025

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...

Company Deals

Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases

Fineline Cube Apr 15, 2025

Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc....

Company Medical Device

Peijia Medical’s TaurusTrio TAV System Accepted for NMPA Review in China

Fineline Cube Apr 15, 2025

China-based Peijia Medical Ltd (HKG: 9996) has announced that the National Medical Products Administration (NMPA)...

Company Drug

HighTide Therapeutics’ HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment

Fineline Cube Apr 15, 2025

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical...

Company Drug

Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259

Fineline Cube Apr 15, 2025

China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance...

Company Deals

Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production

Fineline Cube Apr 15, 2025

Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured...

Company Deals

Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters

Fineline Cube Apr 15, 2025

UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503)...

Company Drug

MSD’s Gardasil 9 Approved in China for Males Aged 16 to 26

Fineline Cube Apr 14, 2025

US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced marketing approval from...

Policy / Regulatory

NHC Urges Hospitals to Establish Healthy Weight Management Clinics by June

Fineline Cube Apr 14, 2025

The National Health Commission (NHC) has issued a notification encouraging eligible Class 3 general hospitals,...

Company Deals

Mabwell and DP Technology Collaborate to Build Biopharma AI Platform for Drug Development

Fineline Cube Apr 14, 2025

Chinese companies Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) and DP Technology have entered into...

Posts pagination

1 … 172 173 174 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.